
- Sample size determination for phase 1 studies
- Evaluation of safety, pharmacokinetic, and pharmacodynamic parameters
- Two-group t-test with a two-sided significance level
- Power analysis for detecting differences in means and standard deviations
- Safety population (participants who received at least one dose of the study drug)
- Pharmacokinetic and pharmacodynamic population
- Intention-to-treat principle for statistical analysis
- Efficacy estimand for pharmacodynamic measures
- Mixed-model repeated-measure analyses
- Absolute values and change from baseline analysis
- Least-squares means (LSMs) and 90% confidence intervals (CIs)
- Unstructured covariance structure and compound symmetric structure in statistical modeling
- Pharmacokinetic dose proportionality analysis
- Log-transformed Cmax and AUC (Area Under the Curve) for dose-normalized geometric means
- Registration of the study at ClinicalTrialsgov, NCT04143802
- Use of SAS version 94 for data analysis
